The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Update on the Clinical Efficacy and Side Effects of Clozapine
Open accessAbstract
Clozapine (CLOZ) is an atypical antipsychotic drug being used with increasing frequency throughout the world and has recently been commercially marketed in the United States. Its unique properties make it a promising but challenging drug to use in the treatment of schizophrenia. In order to use CLOZ most effectively and efficiently, clinicians must be aware of its potential benefits and risks. This report is a review and critical evaluation of current knowledge regarding the clinical efficacy and side effects of CLOZ. Although CLOZ has proven to be effective in some treatment-refractory schizophrenic patients and to produce relatively few extrapyramidal side effects compared to classical neuroleptic drugs, several issues require further investigation including what defines neuroleptic intolerance, the optimal dose range, and the appropriate duration of a CLOZ treatment trial. Similarly, studies are needed to determine what role CLOZ should have in the treatment of patients with predominantly negative symptoms and those patients who are only partially responsive to standard neuroleptics. In addition, important questions remain as to what other conditions might be indications for CLOZ, for example, schizoaffective disorder, affective psychoses, and idiopathic Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Self-citationThe Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
Neuroleptic malignant syndrome
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.10.1137 · Cited by 978
A Survey of Drug-Induced Extrapyramidal Reactions
Ayd, F. J. (1961) · JAMA · doi:10.1001/jama.1961.03040120016004 · Cited by 753
Why Do Schizophrenic Patients Refuse to Take Their Drugs?
Van Putten, T. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760130049008 · Cited by 572
D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
Farde, L., Wiesel, F. A., Nordstr�m, A. L., & Sedvall, G. (1989) · Psychopharmacology · doi:10.1007/bf00442555 · Cited by 325
The Risks and Benefits of Clozapine versus Chlorpromazine
CLAGHORN, J., HONIGFELD, G., ABUZZAHAB, F. S., WANG, R., STEINBOOK, R., TUASON, V., & KLERMAN, G. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198712000-00002 · Cited by 301
Povlsen, U. J., Norrng, U., Fog, R., & Gerlach, J. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb01268.x · Cited by 278
Meltzer, H. Y., Bastani, B., Kwon, K. Y., Ramirez, L. F., Burnett, S., & Sharpe, J. (1989) · Psychopharmacology · doi:10.1007/bf00442563 · Cited by 271
Clozapine: neuroleptic-induced EPS and tardive dyskinesia
Casey, D. E. (1989) · Psychopharmacology · doi:10.1007/bf00442559 · Cited by 251
Lindström, L. H. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb05164.x · Cited by 246
Agranulocytosis during treatment with clozapine
Id�np��n-Heikkil�, J., Alhava, E., Olkinuora, M., & Palva, I. P. (1977) · European Journal of Clinical Pharmacology · doi:10.1007/bf00606409 · Cited by 237
Clozapine: guidelines for clinical management.
Lieberman, J. A., Kane, J. M., & Johns, C. A. (1989) · PubMed · Cited by 226
Self-citationNeuroleptic-induced supersensitivity psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1409 · Cited by 224
Clozapine-induced agranulocytosis: A genetic and epidemiologic study
de la Chapelle, A., Kari, C., Nurminen, M., & Hernberg, S. (1977) · Human Genetics · doi:10.1007/bf00393581 · Cited by 211
HLA-B38, DR4, DQw3 and Clozapine-Induced Agranulocytosis in Jewish Patients With Schizophrenia
Lieberman, J. A. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220061007 · Cited by 207
Self-citationIntegrating incidence and prevalence of tardive dyskinesia.
Kane, J. M., Woerner, M. G., Borenstein, M., Wegner, J. T., & Lieberman, J. A. (1986) · PubMed · Cited by 207
Self-citationEffect of clozapine on human serum prolactin levels
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.12.1550 · Cited by 171
The trial use of clozapine for abnormal involuntary movement disorders
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.3.317 · Cited by 161
Immune and toxic mechanisms in drug-induced agranulocytosis.
Pisciotta, A. V. (1973) · PubMed · Cited by 150
Influence of patient-related variables on clozapine plasma levels
Häring, C., Fleischhacker, W. W., Schett, P., Humpel, C., Barnas, C., & Saria, A. (1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.11.1471 · Cited by 141
Grohmann, R., R�ther, E., Sassim, N., & Schmidt, L. G. (1989) · Psychopharmacology · doi:10.1007/bf00442571 · Cited by 136
Clozapine in the treatment of tremor
Pakkenberg, H., & Pakkenberg, B. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1986.tb03279.x · Cited by 129
Clozapine: an atypical antipsychotic agent.
Ereshefsky, L., Watanabe, & Tran-Johnson, T. K. (1989) · PubMed · Cited by 127
Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs.
Lieberman, J. A., Johns, C. A., Kane, J. M., Rai, K., Pisciotta, A. V., Saltz, B. L., & Howard, A. (1988) · PubMed · Cited by 125
Self-citationHeilmeyer, L. (1948) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1118033 · Cited by 122
Clozapine--a new antipsychotic agent.
Simpson, G. M., & Varga, E. (1974) · PubMed · Cited by 120
Small, J. G., Milstein, V., Marhenke, J. D., et al. (1987) · PubMed · Cited by 117
Apparent Neuroleptic Malignant Syndrome with Clozapine and Lithium
Pope, H. G., Cole, J. O., Choras, P., & Fulwiler, C. (1986) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198608000-00010 · Cited by 109
Clozapine‐responsive tremor in Parkinson's disease
Friedman, J. H., & Lannon, M. C. (1990) · Movement Disorders · doi:10.1002/mds.870050307 · Cited by 109
Marder, S. R., & Putten, T. V. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330099012 · Cited by 94
An example of European multicenter trials: multispectral analysis of clozapine.
Fischer-Cornelssen, K. A., & Uj, F. (1976) · PubMed · Cited by 91
Griffith, R., & Saameli, K. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90135-x · Cited by 89
Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal
Ekblom, B., Eriksson, K., & Lindstr�m, L. H. (1984) · Psychopharmacology · doi:10.1007/bf00464798 · Cited by 88
Sexual Side Effects of Antipsychotic Medication: Evaluation and Interventions
Sullivan, G., & Lukoff, D. G. (1990) · Psychiatric Services · doi:10.1176/ps.41.11.1238 · Cited by 84
Clozapine: Plasma levels and prolactin response
Kane, J. M., Cooper, T. B., Sachar, E. J., Halpern, F. S., & Bailine, S. H. (1981) · Psychopharmacology · doi:10.1007/bf00429215 · Cited by 81
Self-citationClozapine for psychosis in Parkinson's disease
Pfeiffer, R. F., Kang, J. S., Graber, B., Hofman, R., & Wilson, J. (1990) · Movement Disorders · doi:10.1002/mds.870050310 · Cited by 79
Clinical and epidemiologic aspects of tardive dyskinesia.
Baldessarini, R. J. (1985) · PubMed · Cited by 72
Gelenberg, A. J., & Doller, J. C. (1979) · PubMed · Cited by 70
Whitford, G. S. (2014) · Routledge eBooks · doi:10.4324/9781315800998-9 · Cited by 66
Clozapine in the treatment of 121 out-patients
Leppig, M., Bosch, B., Naber, D., et al. (1989) · Psychopharmacology · doi:10.1007/bf00442565 · Cited by 58
Clozapine withdrawal rebound psychosis.
Borison, R. L., Diamond, B. I., Sinha, D., Gupta, R. P., & Ajiboye, P. O. (1988) · PubMed · Cited by 56
Response to clozapine in chronic psychotic patients.
Rr, O., Beake, B., Marby, D. W., et al. (1989) · PubMed · Cited by 52
Friedman, J. H., Max, J. E., & Swift, R. M. (1987) · Clinical Neuropharmacology · doi:10.1097/00002826-198710000-00011 · Cited by 49
Clozapine in the Treatment of Tardive Dyskinesia: an Interim Report
Gerbino, L., Shopsin, B., & Collora, M. (1980) · Springer eBooks · doi:10.1007/978-94-011-6381-1_42 · Cited by 47
Clozapine effects on tardive dyskinesia.
Ja, L., Saltz, B. L., Johns, C. A., Pollack, S. Z., & Kane, J. M. (1989) · PubMed · Cited by 43
Self-citationPredictors of response to clozapine therapy
Honigfeld, G., & Patin, J. R. (1989) · Psychopharmacology · doi:10.1007/bf00442562 · Cited by 40
Clozapine: An Antipsychotic Agent in Parkinsonʼs Disease?
Wolters, E. C., Hurwitz, T. A., Peppard, R. F., & Calne, D. B. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198904000-00001 · Cited by 40
Clozapine in the Treatment of Newly Admitted Schizophrenic Patients A Pilot Study
Chouinard, G., & Annable, L. (1976) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1976.tb02407.x · Cited by 37
Early relapse after sudden withdrawal or dose reduction of clozapine
Per�nyi, A., Kuncz, E., & Bagdy, G. (1985) · Psychopharmacology · doi:10.1007/bf00431719 · Cited by 31
Supersensitivity and clozapine withdrawal
Eklund, K. L. (1987) · Psychopharmacology · doi:10.1007/bf00690943 · Cited by 27
Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
Singh, H., Ji, H., Vitiello, B., & Gm, S. (1990) · PubMed · Cited by 21
Ukai, Y., Taniguchi, N., Ishima, T., & Kimura, K. (1989) · PubMed · Cited by 9
Cited by
Management of treatment resistance in schizophrenia
Conley, R. R., & Kelly, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01271-9 · Cited by 352
The history of clozapine and its emergence in the US market: a review and analysis
Crilly, J. (2007) · History of Psychiatry · doi:10.1177/0957154x07070335 · Cited by 272
Pharmacokinetics and Pharmacodynamics of Clozapine
Jann, M. W., Grimsley, S. R., Gray, E. C., & Chang, W.-H. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324020-00005 · Cited by 257
Dimensions of Outcome with Clozapine
Meltzer, H. Y. (1992) · British Journal of Psychiatry · doi:10.1192/s000712500029692x · Cited by 252
Lieberman, J. A. (1993) · British Journal of Psychiatry · doi:10.1192/s0007125000292544 · Cited by 108
Self-citation
Metadata
- Authors
- Safferman, A., Lieberman, J. A., Kane, J. M., Szymanski, S., & Kinon, B.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-01-01
- Volume
- 17
- Issue
- 2
- Pages
- 247-261
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2036121762
- Cited by
- 301
- References
- 55
- FWCI
- 16.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.